Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms ...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

Laser-produced plasmas have been used to create short bursts of x-rays and to accelerate particles — so-called plasma-based accelerators. Laser produced plasmas are also useful for recreating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spanish plasma-based medicines maker Grifols (MCE: GRF) has announced disappointing top-line data from its Phase III PRECIOSA clinical trial evaluating the potential of long-term albumin treatment ...

US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA. The drug maker’s market capitalization has ...

However, it’s not as easy as it sounds. For a fusion reaction, plasma is required to be heated to hundreds of millions of degrees Celsius — this is seven to eight times more than the ...

Heating plasma to the ultra-high temperatures needed for fusion reactions requires more than turning the dial on a thermostat. Scientists consider multiple methods, one of which involves injecting ...

Instead, he’s a civilian who used some engineering smarts, some widely available parts and a 3D printer to create a functioning weapon that can fire graphite, aluminum, tungsten and even plasma ...

Scientists would like to track electrical activity in the ionosphere by measuring the distribution of plasma, the form matter takes when positive ions are separated from their electrons ...

Berenberg lowered the firm’s price target on Grifols (GRFS) to EUR 19.30 from EUR 19.40 and keeps a Buy rating on the shares. Three things matter for Grifols’ share prices: the business ...